HIV protease (PR) is required for proteolytic maturation in the late phase of HIV replication and represents a prime therapeutic target. The regulation and kinetics of viral polyprotein processing and maturation are currently not understood in detail. Here we design, synthesize, validate and apply a potent, photodegradable HIV PR inhibitor to achieve synchronized induction of proteolysis. The compound exhibits subnanomolar inhibition in vitro. Its photolabile moiety is released on light irradiation, reducing the inhibitory potential by 4 orders of magnitude. We determine the structure of the PR-inhibitor complex, analyze its photolytic products, and show that the enzymatic activity of inhibited PR can be fully restored on inhibitor photolysis. We also demonstrate that proteolysis of immature HIV particles produced in the presence of the inhibitor can be rapidly triggered by light enabling thus to analyze the timing, regulation and spatial requirements of viral processing in real time.

] Department of Infectious Diseases Virology University Hospital Heidelberg Im Neuenheimer Feld 324 69120 Heidelberg Germany [2] Molecular Medicine Partnership Unit Heidelberg Germany

] Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic Gilead Sciences and IOCB Research Center Flemingovo n 2 166 10 Prague 6 Czech Republic [2] Department of Biochemistry Faculty of Science Charles University Prague Hlavova 8 128 43 Prague 2 Czech Republic

Department of Infectious Diseases Virology University Hospital Heidelberg Im Neuenheimer Feld 324 69120 Heidelberg Germany

Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic Gilead Sciences and IOCB Research Center Flemingovo n 2 166 10 Prague 6 Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc16010479

003      

CZ-PrNML

005      

20220614101825.0

007      

ta

008      

160408s2015 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1038/ncomms7461 $2 doi

024    7_

$a 10.1038/ncomms7461 $2 doi

035    __

$a (PubMed)25751579

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Schimer, Jiří $u 1] Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center, Flemingovo n.2, 166 10, Prague 6, Czech Republic [2] Department of Biochemistry, Faculty of Science, Charles University in Prague, Hlavova 8, 128 43, Prague 2, Czech Republic.

245    10

$a Triggering HIV polyprotein processing by light using rapid photodegradation of a tight-binding protease inhibitor / $c J. Schimer, M. Pávová, M. Anders, P. Pachl, P. Šácha, P. Cígler, J. Weber, P. Majer, P. Řezáčová, HG. Kräusslich, B. Müller, J. Konvalinka,

520    9_

$a HIV protease (PR) is required for proteolytic maturation in the late phase of HIV replication and represents a prime therapeutic target. The regulation and kinetics of viral polyprotein processing and maturation are currently not understood in detail. Here we design, synthesize, validate and apply a potent, photodegradable HIV PR inhibitor to achieve synchronized induction of proteolysis. The compound exhibits subnanomolar inhibition in vitro. Its photolabile moiety is released on light irradiation, reducing the inhibitory potential by 4 orders of magnitude. We determine the structure of the PR-inhibitor complex, analyze its photolytic products, and show that the enzymatic activity of inhibited PR can be fully restored on inhibitor photolysis. We also demonstrate that proteolysis of immature HIV particles produced in the presence of the inhibitor can be rapidly triggered by light enabling thus to analyze the timing, regulation and spatial requirements of viral processing in real time.

650    _2

$a aminokumariny $x chemická syntéza $x farmakologie $7 D049933

650    _2

$a vazebná místa $7 D001665

650    _2

$a karbamáty $x chemická syntéza $x farmakologie $7 D002219

650    _2

$a HEK293 buňky $7 D057809

650    _2

$a HIV-proteasa $x chemie $x metabolismus $7 D016333

650    _2

$a inhibitory HIV-proteasy $x chemická syntéza $x farmakologie $7 D017320

650    _2

$a HIV-1 $x účinky léků $x fyziologie $x účinky záření $7 D015497

650    _2

$a lidé $7 D006801

650    _2

$a kinetika $7 D007700

650    _2

$a světlo $7 D008027

650    _2

$a molekulární modely $7 D008958

650    _2

$a fotolýza $7 D010782

650    _2

$a vazba proteinů $7 D011485

650    _2

$a proteinové prekurzory $x antagonisté a inhibitory $x chemie $x metabolismus $7 D011498

650    _2

$a proteolýza $x účinky léků $7 D059748

650    _2

$a časové faktory $7 D013997

650    _2

$a valin $x analogy a deriváty $x chemická syntéza $x farmakologie $7 D014633

650    _2

$a replikace viru $7 D014779

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Pávová, Marcela $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center, Flemingovo n.2, 166 10, Prague 6, Czech Republic.

700    1_

$a Anders, Maria $u Department of Infectious Diseases, Virology, University Hospital Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany. $7 gn_A_00006046

700    1_

$a Pachl, Petr $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center, Flemingovo n.2, 166 10, Prague 6, Czech Republic.

700    1_

$a Šácha, Pavel $u 1] Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center, Flemingovo n.2, 166 10, Prague 6, Czech Republic [2] Department of Biochemistry, Faculty of Science, Charles University in Prague, Hlavova 8, 128 43, Prague 2, Czech Republic.

700    1_

$a Cígler, Petr $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center, Flemingovo n.2, 166 10, Prague 6, Czech Republic.

700    1_

$a Weber, Jan $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center, Flemingovo n.2, 166 10, Prague 6, Czech Republic.

700    1_

$a Majer, Pavel $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center, Flemingovo n.2, 166 10, Prague 6, Czech Republic.

700    1_

$a Řezáčová, Pavlína $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center, Flemingovo n.2, 166 10, Prague 6, Czech Republic.

700    1_

$a Kräusslich, Hans-Georg, $u 1] Department of Infectious Diseases, Virology, University Hospital Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany [2] Molecular Medicine Partnership Unit, Heidelberg, Germany. $d 1958- $7 xx0273885

700    1_

$a Müller, Barbara $u 1] Department of Infectious Diseases, Virology, University Hospital Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany [2] Molecular Medicine Partnership Unit, Heidelberg, Germany.

700    1_

$a Konvalinka, Jan $u 1] Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center, Flemingovo n.2, 166 10, Prague 6, Czech Republic [2] Department of Biochemistry, Faculty of Science, Charles University in Prague, Hlavova 8, 128 43, Prague 2, Czech Republic.

773    0_

$w MED00184850 $t Nature communications $x 2041-1723 $g Roč. 6, č. - (2015), s. 6461

856    41

$u https://pubmed.ncbi.nlm.nih.gov/25751579 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20160408 $b ABA008

991    __

$a 20220614101822 $b ABA008

999    __

$a ok $b bmc $g 1113908 $s 934847

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2015 $b 6 $c - $d 6461 $e 20150309 $i 2041-1723 $m Nature communications $n Nat Commun $x MED00184850

LZP    __

$a Pubmed-20160408